Update in tuberculosis and nontuberculous mycobacterial disease 2011

American Journal of Respiratory and Critical Care Medicine

Volumn 185, Issue 12, 2012, Pages 1266-1270

  Nahid, Payam ^a   Menzies, Dick ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; BEDAQUILINE; CORTICOSTEROID; ETHAMBUTOL; FLUTICASONE; GAMMA INTERFERON; ISONIAZID; PYRAZINAMIDE; RESERPINE; RIFAMYCIN; RIFAPENTINE; VERAPAMIL;

ACID FAST BACTERIUM; ASTHMA; ATYPICAL MYCOBACTERIOSIS; BAGG ALBINO MOUSE; BCG VACCINATION; BLOOD LEVEL; CANADA; CHRONIC COUGH; COST EFFECTIVENESS ANALYSIS; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FLUORESCENCE MICROSCOPY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LATENT TUBERCULOSIS; LOWEST INCOME GROUP; LUNG TUBERCULOSIS; MORBIDITY; MYCOBACTERIUM ABSCESSUS; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PULMONOLOGY; REVIEW; SENSITIVITY ANALYSIS; SMEAR; THORAX RADIOGRAPHY; TUBERCULIN TEST; TUBERCULOSIS; UNITED STATES; WORLD HEALTH ORGANIZATION;

ANIMALS; ANTITUBERCULAR AGENTS; COMMUNICABLE DISEASE CONTROL; COMORBIDITY; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; INCIDENCE; LATENT TUBERCULOSIS; MALE; MICE; MICE, INBRED BALB C; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUBERCULOSIS; WORLD HEALTH; WORLD HEALTH ORGANIZATION;

EID: 84862528564     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201203-0494UP     Document Type: Review

References (29)

1. World Health Organization. World Health Organization report: global tuberculosis control. Geneva, Switzerland; 2011.
2. Lonnroth K, Castro KG, Chakaya JM, Chauhan LS, Floyd K, Glaziou P, Raviglione MC. Tuberculosis control and elimination 2010-50: cure, care, and social development. Lancet 2010;375:1814-1829.
3. van't Hoog AH, Laserson KF, Githui WA, Meme HK, Agaya JA, Odeny LO, Muchiri BG, Marston BJ, DeCock KM, Borgdorff MW. High prevalence of pulmonary tuberculosis and inadequate case finding in rural western kenya. Am J Respir Crit Care Med 2011;183:1245-1253.
4. Brassard P, Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and risk of tuberculosis in patients with respiratory diseases. Am J Respir Crit Care Med 2011;183:675-678.
5. Anandaiah A, Dheda K, Keane J, Koziel H, Moore DA, Patel NR. Novel developments in the epidemic of human immunodeficiency virus and tuberculosis coinfection. Am J Respir Crit Care Med 2011;183:987-997.
6. Cattamanchi A, Huang L, Worodria W, den Boon S, Kalema N, Katagira W, Byanyima P, Yoo S, Matovu J, Hopewell PC, et al. Integrated strategies to optimize sputum smear microscopy: a prospective observational study. Am J Respir Crit Care Med 2011;183:547-551.
7. Khan FA, Minion J, Pai M, Royce S, Burman W, Harries AD, Menzies D. Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis. Clin Infect Dis 2010;50:1288-1299.
8. Swaminathan S, Narendran G, Venkatesan P, Iliayas S, Santhanakrishnan R, Menon PA, Padmapriyadarsini C, Ramachandran R, Chinnaiyan P, Suhadev M, et al. Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial. Am J Respir Crit Care Med 2010;181:743-751.
9. Linas BP, Wong AY, Freedberg KA, Horsburgh CR Jr. Priorities for screening and treatment of latent tuberculosis infection in the united states. Am J Respir Crit Care Med 2011;184:590-601.
10. Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven- Sizemore E, Hackman J, Hamilton CD, Menzies D, Kerrigan A, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011;365:2155-2166.
11. Cuevas LE, Yassin MA, Al-Sonboli N, Lawson L, Arbide I, Al-Aghbari N, Sherchand JB, Al-Absi A, Emenyonu EN, Merid Y, et al. A multicountry non-inferiority cluster randomized trial of frontloaded smear microscopy for the diagnosis of pulmonary tuberculosis. PLoS Med 2011;8:e1000443.
12. Davis J, Katamba A, Vasquez J, Crawford E, Sserwanga A, Kakeeto S, Kizito F, Dorsey G, den Boon S, Vittinghoff E, et al. Evaluating tuberculosis case detection via real-time monitoring of tuberculosis diagnostic services. Am J Respir Crit Care Med 2011;184:362-367.
13. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, Allen J, Tahirli R, Blakemore R, Rustomjee R, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010;363:1005-1015.
14. Lawn SD, Brooks SV, Kranzer K, Nicol MP, Whitelaw A, Vogt M, Bekker LG, Wood R. Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the xpert mtb/rif assay: a prospective study. PLoS Med 2011;8:e1001067.
15. Scott LE, McCarthy K, Gous N, Nduna M, Van Rie A, Sanne I, Venter WF, Duse A, Stevens W. Comparison of xpert mtb/rif with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study. PLoS Med 2011;8:e1001061.
16. Theron G, Peter J, van Zyl-Smit R, Mishra H, Streicher E, Murray S, Dawson R, Whitelaw A, Hoelscher M, Sharma S, et al. Evaluation of the xpert mtb/rif assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting. Am J Respir Crit Care Med 2011;184:132-140.
17. Blakemore R, Nabeta P, Davidow AL, Vadwai V, Tahirli R, Munsamy V, Nicol M, Jones M, Persing DH, Hillemann D, et al. A multi-site assessment of the quantitative capabilities of the Xpert(r) MTB/RIF assay. Am J Respir Crit Care Med 2011;184:1076-1084.
18. Shah NS, Moodley P, Babaria P, Moodley S, Ramtahal M, Richardson J, Heysell S, Li X, Moll A, Friedland G, et al. Rapid diagnosis of tuberculosis and multidrug resistance by the microscopic-observation drug-susceptibility assay. Am J Respir Crit Care Med 2011;183:1427-1433.
19. Getahun H, Kittikraisak W, Heilig CM, Corbett EL, Ayles H, Cain KP, Grant AD, Churchyard GJ, Kimerling M, Shah S, et al. Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. PLoS Med 2011;8:e1000391.
20. Samandari T, Bishai D, Luteijn M, Mosimaneotsile B, Motsamai O, Postma M, Hubben G. Costs and consequences of additional chest x-ray in a tuberculosis prevention program in Botswana. Am J Respir Crit Care Med 2011;183:1103-1111.
21. Diel R, Loddenkemper R, Niemann S, Meywald-Walter K, Nienhaus A. Negative and positive predictive value of a whole-blood interferon- {gamma} release assay for developing active tuberculosis: an update. Am J Respir Crit Care Med 2011;183:88-95.
22. Rangaka MX, Wilkinson KA, Glynn JR, Ling D, Menzies D, Mwansa- Kambafwile J, Fielding K, Wilkinson RJ, Pai M. Predictive value of interferon-gamma release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2012;12:45-55.
23. Zhang M, Li SY, Rosenthal IM, Almeida DV, Ahmad Z, Converse PJ, Peloquin CA, Nuermberger EL, Grosset JH. Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice. Am J Respir Crit Care Med 2011;183:1254-1261.
24. Nahid P, Saukkonen J, Mac Kenzie WR, Johnson JL, Phillips PP, Andersen J, Bliven-Sizemore E, Belisle JT, Boom WH, Luetkemeyer A, et al. CDC/NIH workshop. Tuberculosis biomarker and surrogate endpoint research roadmap. Am J Respir Crit Care Med 2011;184:972-979.
25. Louw GE, Warren RM, Gey van Pittius NC, Leon R, Jimenez A, Hernandez-Pando R, McEvoy CR, Grobbelaar M, Murray M, van Helden PD, et al. Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant mycobacterium tuberculosis through efflux. Am J Respir Crit Care Med 2011;184:269-276.
26. Udwadia ZF, Amale RA, Ajbani KK, Rodrigues C. Totally drug-resistant tuberculosis in india. Clin Infect Dis 2012;54:579-581.
27. Zhang T, Li SY, Williams KN, Andries K, Nuermberger EL. Short-course chemotherapy with tmc207 and rifapentine in a murine model of latent tuberculosis infection. Am J Respir Crit Care Med 2011;184:732-737.
28. Luetkemeyer AF, Getahun H, Chamie G, Lienhardt C, Havlir DV. Tuberculosis drug development: ensuring people living with HIV are not left behind. Am J Respir Crit Care Med 2011;184:1107-1113.
29. Koh WJ, Jeon K, Lee NY, Kim BJ, Kook YH, Lee SH, Park YK, Kim CK, Shin SJ, Huitt GA, et al. Clinical significance of differentiation of mycobacterium massiliense from mycobacterium abscessus. Am J Respir Crit Care Med 2011;183:405-410.